Bracco Diagnostics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bracco Diagnostics (US): 4 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel